Feature | March 19, 2015

Dual Antiplatelet Therapy Associated with Increased Mortality after Drug-Eluting Stent Implantation

Meta-analysis finds longer DAPT associated with 22 percent increase in all-cause mortality

dual antiplatelet therapy, DAPT, mortality, DES implantation, CRF, length

March 19, 2015 — Data from a meta-analysis published recently in The Lancet found that extended-duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT.

The optimal duration of DAPT has been a matter of debate since the introduction of DES. A meta-analysis using multiple analytical approaches to investigate mortality and other clinical outcomes with different DAPT strategies was conducted.

Researchers examined 31,666 patients from 10 randomized trials comparing different durations of DAPT in patients treated with DES. The primary endpoint was all-cause mortality. Secondary pre-specified endpoints included cardiac death, non-cardiac death, myocardial infarction (MI), stroke, stent thrombosis (definite or probable), major bleeding and any bleeding. DAPT duration was categorized in each study as “shorter” versus “longer,” and ?6 months versus 1 year versus ?1 year. Analyses were performed by both frequentist and Bayesian approaches.

Shorter DAPT was associated with significantly lower rates of all-cause mortality compared to longer DAPT (HR=0.82, 95 percent CI 0.69-0.98, p=0.02; number needed to treat [NNT] =325). This difference was driven by a significant reduction of non-cardiac mortality with shorter DAPT (HR=0.67, 95 percent CI 0.51-0.89, p=0.006; NNT=347). No significant difference in cardiac mortality was found between the shorter and longer strategies (HR=0.93, 95% CI 0.73-1.17, p=0.52). No significant heterogeneity across trials or between pooled trials stratified by DAPT duration was apparent.

Shorter DAPT was also associated with significantly lower rates of major bleeding (HR=0.58, 95 percent CI 0.47- 0.72, p<0.0001; NNT=166) and any bleeding (HR=0.56, 95 percent CI 0.48-0.66, p<0.0001; NNT=83) compared to longer DAPT. However, shorter DAPT was associated with significantly higher rates of MI (HR=1.51, 95 percent CI 1.28-1.77, p<0.0001; number needed to harm [NNH] =129) and definite or probable stent thrombosis (HR=2.04, 95 percent CI 1.48-2.80, p<0.0001; NNH=248) compared to longer DAPT with moderate heterogeneity across trials. Stroke rates did not vary with DAPT duration.

Additional subgroup network meta-analyses found patients treated with ?6-month DAPT and 1-year DAPT had higher risk of MI and stent thrombosis but lower risk of mortality compared to patients treated with >1-year DAPT. Patients treated with ?6-month DAPT had similar rates of mortality, MI and stent thrombosis, but lower rates of major bleeding compared to 1-year DAPT.

“This meta-analysis found that in patients treated with DES, longer DAPT was associated with a 22 percent increased rate of all-cause mortality due to a 49 percent increased rate in non-cardiac mortality, with no significant difference in cardiac mortality. These results support a short-term (3 or 6 months) DAPT strategy in most patients, especially those at low risk of recurrent coronary events and stent thrombosis, and at high risk of bleeding.” said Gregg W. Stone, M.D., the study’s senior author. Stone is co-director of the Cardiovascular Research Foundation’s Medical Research and Education Division. He is also professor of medicine at Columbia University College of Physicians and Surgeons and director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center.

“However, an extended DAPT strategy (longer than 1 year) may still be appropriate in selected patients in whom prevention of stent and non-stent related coronary events are likely to offset the adverse events associated with extended duration antiplatelet therapy,” he added

“Establishing the optimal duration of DAPT after DES implantation is extremely important in balancing the risks of ischemic and bleeding complications. Therefore, an individualized approach in which the benefit-risk profile for each patient should be carefully considered. Further studies are required to model the demographic, laboratory-based and genetic variables that affect the benefit vs. risk balance of prolonged DAPT that might remove the guesswork from this equation,” concluded Stone.

For more information: www.crf.org

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init